Telix Pharmaceuticals Limited today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx ...

Ms. Whitaker is an accomplished C-suite leader, most recently as Chair and CEO of Aerami Therapeutics Holdings Inc. During her executive career she has held senior leadership roles at GlaxoSmithKline ...

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

The broker is feeling bullish on these names this month. Let's find out why. The post Bell Potter names the best ASX 200 ...

MELBOURNE - Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX), a pharmaceutical company with a market capitalization of $5.58 billion and strong financial health according to InvestingPro ...

Dr. David N. Cade, Telix Group Chief Medical Officer, added, “We are pleased that a first patient has been imaged in the first-in-human ZOLAR trial, which is designed to inform both the ...

MELBOURNE, Australia, April 2, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ...